The increase in cancer diagnoses and cancer deaths, severe side effects of existing treatments and resistance to traditional treatments have generated a need for new anticancer treatments. Glioblastoma multiforme (GBM) is the most common, malignant and aggressive brain cancer. Despite many innovations regarding GBM treatment, the final outcome is still very poor, making it necessary to develop new therapeutic approaches. Cold atmospheric plasma (CAP) as well as plasma-activated liquids (PAL) are being studied as new possible approaches against cancer. The anticancer activity of PAL such as “plasma-activated water” (PAW) is dependent on the reactive chemical compounds present in the solution. Possible combinatory effects with conventional therapies, such as chemotherapeutics, may expand the potential of PAL for cancer treatment. We aim to explore the therapeutic properties of a combination of PAW and topotecan (TPT), an antineoplastic agent with major cytotoxic effects during the S phase of the cell cycle, on a GBM cancer cell line (U-251mg). Combined treatments with PAW and TPT showed a reduction in the metabolic activity and cell mass, an increase in apoptotic cell death and a reduction in the long-term survival. Single applications of PAW+TPT treatments showed a cytotoxic effect in the short term and an antiproliferative effect in the long term, warranting future exploration of combining PAW with chemotherapeutic agents as new therapeutic approaches.
癌症诊断与死亡病例的增加、现有治疗手段的严重副作用以及对传统疗法的耐药性，催生了对新型抗癌疗法的需求。多形性胶质母细胞瘤（GBM）是最常见、恶性程度最高且最具侵袭性的脑癌。尽管针对GBM的治疗已有诸多创新，但最终预后仍然极差，因此亟需开发新的治疗方法。冷大气压等离子体（CAP）及其活化液体（PAL）作为潜在的新型抗癌手段正在被广泛研究。以"等离子体活化水"（PAW）为代表的PAL的抗癌活性取决于溶液中存在的活性化学成分。与传统疗法（如化疗药物）的潜在协同效应可能拓展PAL在癌症治疗中的应用前景。本研究旨在探索PAW与拓扑替康（TPT）联合治疗对GBM细胞系（U-251mg）的作用机制，其中TPT作为主要在细胞周期S期发挥细胞毒作用的抗肿瘤药物。实验结果显示：PAW与TPT联合治疗能显著降低细胞代谢活性与细胞质量，促进细胞凋亡，并抑制长期存活率。单次PAW+TPT联合处理在短期内呈现细胞毒性效应，长期则表现出抗增殖作用，这为未来探索PAW与化疗药物联合应用作为新型治疗策略提供了重要依据。
Combined Effect of Plasma-Activated Water and Topotecan in Glioblastoma Cells
肿瘤(癌症)患者之家